Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG2001 tosylate tablets in KRAS-mutant advanced solid tumors
CTR20231788Phase 2Active
- Sponsor
- Zelgen
- Start
- Aug 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZG2001 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Zelgen. Started Aug 2023; status: active.
02
Drugs
ZG2001
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20231788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231788.